The
United Kingdom Immunotherapy Market is anticipated to grow at a significant
rate in the projected period, 2024-2028. Immunotherapy has revolutionized the
field of healthcare by harnessing the power of the immune system to fight diseases
such as cancer, autoimmune disorders, and infectious diseases. In the United
Kingdom, the immunotherapy market has experienced significant growth in recent
years, with innovative therapies providing new hope for patients and healthcare
providers alike. The United Kingdom boasts a robust ecosystem of pharmaceutical
companies, research institutions, and healthcare providers actively engaged in
the development and adoption of immunotherapy.
Immunotherapy
makes use of chemicals produced by the body or in a lab to strengthen the
immune system and assist the body in locating and eliminating cancer cells.
Numerous forms of cancer can be treated using immunotherapy. It may be used
alone or in conjunction with other cancer treatments such as chemotherapy. When
other therapies fail, immunotherapy may be effective. Immunotherapy can help
some tumors, such as skin cancer, that do not react well to chemotherapy or
radiation, start to disappear, leading to the growth of the United Kingdom
Immunotherapy Market. Compared to other therapies, it has fewer negative
effects. This is due to the fact that only the immune system is affected, not
all of the body's cells.
The
UK has witnessed remarkable advancements in various immunotherapy approaches.
One notable breakthrough is the development of immune checkpoint inhibitors,
such as pembrolizumab and nivolumab, which have shown exceptional efficacy in
treating various types of cancer. These therapies work by targeting specific
molecules that inhibit the immune system's response, thereby reactivating the
body's natural defenses against cancer cells. Another significant advancement
is the advent of CAR-T cell therapy, a form of adoptive cell transfer. This
groundbreaking approach involves modifying a patient's T cells to express
chimeric antigen receptors (CARs) that can recognize and eliminate cancer
cells. CAR-T therapies, such as Kymriah and Yescarta, have demonstrated
remarkable success in treating certain types of leukemia and lymphoma, which is
expected to grow the United Kingdom Immunotherapy Market in the forecast
period.
According
to the International Agency for Research on Cancer, 457,960 new cancer cases
and 179,648 cancer deaths were reported in the United Kingdom in 2020.
Growing
Adoption of Liquid Biopsy Propels United Kingdom's Immunotherapy Market
Immunotherapy
has revolutionized cancer treatment, offering new hope to patients by
harnessing the body's immune system to fight cancer cells. In recent years, the
United Kingdom has witnessed a significant shift in cancer diagnostics and
treatment, with liquid biopsy emerging as a preferred alternative to
traditional tissue biopsy. This non-invasive technique has gained traction and
is driving the growth of the country's immunotherapy market.
Download Free Sample Report
Liquid
biopsy enhances the ability to identify patients who are most likely to benefit
from immunotherapy. By profiling circulating tumor DNA, clinicians can predict
response rates and select patients who have specific genetic alterations or
biomarkers associated with a favorable immunotherapy response. This
personalized approach leads to improved patient outcomes and cost-effective
utilization of immunotherapies, propelling the growth of the United Kingdom
Immunotherapy Market.
Liquid
biopsy facilitates patient enrollment in clinical trials by identifying
individuals with specific genetic alterations or biomarkers relevant to the
trial's target population. This streamlined process accelerates the development
of novel immunotherapies and enables access to cutting-edge treatments for patients.
Liquid biopsy also enables regular monitoring of treatment response and disease
progression. This monitoring allows for timely modifications to immunotherapy
regimens, ensuring optimal treatment outcomes.
Additionally,
liquid biopsy can aid in detecting minimal residual disease, allowing for
earlier intervention and potentially preventing relapse, which is expected to
propel the growth of the United Kingdom Immunotherapy Market. Furthermore, the
ability to perform repeated liquid biopsies during the course of treatment
provides real-time insights into the effectiveness of therapy. By monitoring
circulating tumor DNA or RNA, clinicians can identify emerging resistance
mechanisms, enabling timely adjustments to treatment plans and personalized
care, hence propelling the growth of the United Kingdom's Immunotherapy Market
in the forecast period.
Expanding usage of Target Therapy Propels the United
Kingdom Immunotherapy Market
The United Kingdom has been investing in the
development of its health systems to improve patient care and streamline
numerous operations. According to the Office for National Statistics, in
2021, the total current healthcare expenditure increased by 7.1% in real terms,
compared to 10.0% in 2020, after accounting for the effects of inflation on the
economy. The United Kingdom Immunotherapy Market has witnessed a
significant surge in recent years, largely driven by the increasing adoption of
targeted therapy. Targeted therapy, also known as precision medicine, is a
revolutionary approach that tailors treatment based on an individual's genetic
makeup and specific disease characteristics. This personalized approach has
gained immense popularity and become a game-changer in the field of
immunotherapy.
One of the key factors contributing to the rising
adoption of targeted therapy in the United Kingdom is the remarkable
advancements in genomic research and technology. The availability of advanced
genetic testing methods has enabled healthcare professionals to identify
specific genetic alterations or biomarkers in patients, helping them select the
most suitable targeted therapies and leading to the expansion of the United
Kingdom Immunotherapy Market. This precise approach ensures that patients
receive treatments that are more likely to be effective and minimizes unnecessary
side effects.
Another crucial driver for the increased adoption
of targeted therapy is the growing availability and accessibility of these
treatments in the United Kingdom. Pharmaceutical companies are heavily investing
in research and development to bring new targeted therapies to the market.
Regulatory bodies have also streamlined the approval process, allowing faster
access to these innovative treatments. Moreover, advancements in manufacturing
and distribution processes have made targeted therapies more accessible to
patients across the country.
The benefits of targeted therapy are not limited to
improved treatment outcomes and accessibility. This approach also contributes
to cost savings in the long run. By precisely targeting the disease-causing
mechanisms, targeted therapies can reduce the need for extensive and costly
treatments, such as chemotherapy or radiation therapy, which often have
significant side effects. Additionally, targeted therapy can potentially
shorten the treatment duration, resulting in lower healthcare costs and a more
efficient allocation of resources.
The increasing adoption of targeted therapy in the
United Kingdom Immunotherapy Market has not only transformed the treatment
landscape but has also stimulated research and development in the field.
Pharmaceutical companies and academic institutions are investing in further
understanding the underlying mechanisms of diseases and developing new targeted
therapies to address unmet medical needs, leading to the growth of the United
Kingdom Immunotherapy Market.
Recent Developments
- In May
2023, the immunotherapy medication pembrolizumab (Keytruda) became accessible
to people with certain types of advanced cervical cancer in England and
Scotland. According to preliminary trial findings, pembrolizumab can, on
average, delay the progression of some terminal cervical cancers for 8 months
longer than existing therapies and might enable some cervical cancer
patients to live longer overall. It is the first immunotherapy to be
approved in the UK for the treatment of cervical cancer.
- In
February 2023, Dxcover raised USD12.40 million to develop a pioneering
liquid biopsy platform for early-stage cancers.
Mergers and Acquisitions
- In
November 2021, a collaboration between the Royal Marsden NHS Foundation
Trust and Guardant Health, a leading precision oncology company, resulted
in the establishment of a cutting-edge liquid biopsy testing center for
cancer clinical diagnosis and research. The Royal Marsden has also
utilized liquid biopsies in clinical trials and has developed its own
testing capabilities. On the other hand, the partnership with Guardant
Health will ensure that researchers have access to more powerful tools
based on massive datasets and sophisticated analytics, helping to identify
more cancer patients for clinical trials with targeted treatments.
Market
Segmentation
United Kingdom Immunotherapy Market is segmented
into Technology Type, Indication Type,
End User, Region and Competitive Landscape.
Based on technology type, the market is divided into monoclonal antibodies,
cytokines & immunomodulators, inhibitors and others. Based on Indication
Type, the Market is divided into Oncology, Autoimmune Disease, Infectious Diseases
and Others. Based on End User, the United Kingdom Immunotherapy Market is
categorized into Hospitals & Clinics, Ambulatory Care Centers, Research
& Academic Institutions and Others. Based on Region, the United Kingdom Immunotherapy
Market is segmented into Scotland, South-East, London, South-West, East-Anglia,
Yorkshire & Humberside, and East Midlands.
Company
Profiles
Johnson & Johnson, Novartis AG, Bayer AG, AstraZeneca,
Pfizer Inc., Sanofi, GlaxoSmithKline plc, Amgen, Inc, AbbVie, Inc, F. Hoffmann-La
Roche Ltd are some of the key players of United Kingdom Immunotherapy market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast,
company shares, competitive landscape, growth factors, and trends
|
|
Segments covered
|
Technology Type
Indication Type
End User
Region
|
|
Country scope
|
Scotland,
South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and
East Midlands
|
|
Key companies
profiled
|
Johnson & Johnson, Novartis AG, Bayer AG, AstraZeneca, Pfizer
Inc., Sanofi, GlaxoSmithKline plc, Amgen, Inc, AbbVie, Inc, F. Hoffmann-La
Roche Ltd
|
|
Customization scope
|
10% free report customization with purchase.
Addition or alteration to country, regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized
purchase options to meet your exact research needs.
|
|
Delivery Format
|
PDF and Excel through Email (We can also provide the
editable version of the report in PPT/Word format on special request)
|
Report
Scope:
In
this report, United Kingdom Immunotherapy Market has been segmented into the following
categories, in addition to the industry trends, which have also been detailed below:
- United Kingdom Immunotherapy Market, By Technology
Type:
- Monoclonal Antibodies
- Cytokines & Immunomodulators
- Inhibitors
- Others
- United Kingdom Immunotherapy Market, By Indication
Type:
- Oncology
- Autoimmune Disease
- Infectious Diseases
- Others
- United Kingdom Immunotherapy Market, By End
User:
- Hospitals & Clinics
- Ambulatory Care Centers
- Research & Academic Institutions
- Others
- United Kingdom Immunotherapy Market, By Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire & Humberside
- East Midlands
Competitive
landscape
Company
Profiles: Detailed
analysis of the major companies in United Kingdom Immunotherapy market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed
analysis and profiling of additional market players (up to five).
United Kingdom Immunotherapy Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]